These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8313356)

  • 1. Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin: therapeutic effect in mice bearing lung metastases.
    Mandruzzato S; Rosato A; Bronte V; Zanovello P; Amboldi N; Ballinari D; Collavo D
    Cancer Res; 1994 Feb; 54(4):1016-20. PubMed ID: 8313356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases.
    Zanovello P; Rosato A; Bronte V; Mandruzzato S; Cerundolo V; Collavo D
    Cancer Immunol Immunother; 1992; 35(1):27-32. PubMed ID: 1611620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
    Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
    Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutical effect of 4'-deoxy-4'-iododoxorubicin-loaded LAK cells in mice bearing lung metastases.
    Mandruzzato S; Rosato A; Bronte V; Pollis F; Zambon A; Zanovello P; Collavo D
    Pharmacol Res; 1992 Sep; 26 Suppl 2():124-5. PubMed ID: 1409274
    [No Abstract]   [Full Text] [Related]  

  • 6. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
    Tjota A; Zhang YQ; Piedmonte MR; Lee CL
    J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals.
    Kjaergaard J; Hokland ME; Agger R; Skovbo A; Nannmark U; Basse PH
    Cancer Immunol Immunother; 2000 Jan; 48(10):550-60. PubMed ID: 10630307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.
    Kuroki Y; Ochiai H; Kurokawa M; Niwayama S; Kishimoto C; Tazawa K; Fujimaki M
    J Cancer Res Clin Oncol; 1991; 117(2):109-14. PubMed ID: 2007609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases.
    Basse P; Herberman RB; Nannmark U; Johansson BR; Hokland M; Wasserman K; Goldfarb RH
    J Exp Med; 1991 Aug; 174(2):479-88. PubMed ID: 1856630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
    Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
    Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
    Basse PH
    APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats.
    Felgar RE; Hiserodt JC
    Cell Immunol; 1990 Sep; 129(2):288-98. PubMed ID: 2383892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy of intracerebral metastases in mice.
    McCutcheon IE; Baranco RA; Katz DA; Saris SC
    J Neurosurg; 1990 Jan; 72(1):102-9. PubMed ID: 2294169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infiltration patterns of short- and long-term cultured A-NK and T-LAK cells following adoptive immunotherapy.
    Kjaergaard J; Hokland M; Nannmark U; Hokland P; Basse P
    Scand J Immunol; 1998 Jun; 47(6):532-40. PubMed ID: 9652820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.